James McKiernan, MD
Dr. James McKiernan practices urology at New York-Presbyterian Hospital, specializing in urologic oncology, and has conducted multiple early-phase human trials of intravesical taxanes for bladder cancer.

  • 2010: Professor of Clinical Urology, Columbia
  • 2007: Awarded John and Irene Given endowed Chair in Urology, Columbia
  • 2006: Vice Chairman of Urology and Director of Urologic Oncology, Columbia
  • 2001: Fellowship in Urologic Oncology, Memorial Sloan-Kettering Cancer Center.
  • 1993: MD, Columbia University College of Physicians and Surgeons
  • 1989: BA in Biology, Johns Hopkins University

Alan So, MD, FRCSC
Alan So is the Chair of the Urology Surgical Tumour Group at the BC Cancer Agency and a Surgeon at the Prostate Centre at Vancouver General Hospital.
Dr. So conducts numerous clinical trials as a member of National Cancer Institute of Canada GU Clinical Trials Group and Canadian Uro-Oncology Group and currently leads the Clinical Trials Unit at the Vancouver Prostate Cancer (VPC). His research under the guidance of Dr. Martin Gleave of the VPC focuses primarily on bladder cancer, and he leads the animal tumor model work for STK-01. Dr. So also advises on clinical strategy.

  • 2010-present: Associate Professor, Urological Sciences, UBC
  • 2002-2005: Fellow in Uro-oncology, Vancouver Prostate Centre
  • 2002: Fellowship of Royal College of Surgeons of Canada
  • 1997: MD, University of Alberta
  • 1995: B.Sc. University of Alberta

Peter Black, MD
Peter Black practices at Vancouver General Hospital, and treats all urologic cancers including prostate, bladder, renal and testicular carcinoma, with a special clinical focus on bladder cancer and robotic surgery. Dr. Black has established a laboratory research program at the Vancouver Prostate Centre, investigating novel targeted agents in the treatment of bladder cancer.

  • Assistant Professor, Department of Urologic Sciences, UBC
  • Research Scientist, Vancouver Prostate Centre
  • Active Staff, Vancouver General Hospital, UBC Hospital, St. Paul’s Hospital and Mount Saint Joseph’s Hospital
  • CUA and former AUA Scholar
  • Urologic Oncology Fellowship, M.D. Anderson Cancer Center
  • Urology Residency, University of Washington, Seattle
  • M.D. Johannes Gutenberg University, Mainz, Germany
  • B.Sc. University of British Columbia

Michael O’Donnell, MD
Michael O’Donnell is a board-certified urologist specializing in bladder cancer. His basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy, particularly the anti-cancer mechanisms of BCG.  Dr. O’Donnell has pioneered several new sequential combination therapies involving adriamycin, gemcitabine, docetaxel and mitomycin for treating BCG-resistant/recurrent bladder cancers. His research efforts also include exploration of methods to detect bladder cancer at earlier stages. He is currently lead investigator on two national clinical trials, including a >1000 patient trial evaluating BCG in combination with interferon, holds several US patents, and serves on the editorial board of the Journal of Urology. Dr. O’Donnell is Professor of Urology at the University of Iowa.

  • 2000: Associate Prof University of Iowa Dept of Urology & Member, Holden Comprehensive Cancer Center
  • 1999-2000: Director, Beth Israel Deaconess Medical Center Bladder Cancer Center
  • 1997: Consultant Urologist, Harvard University Health Services & Assistant Professor, Surgery, Harvard Medical School
  • 1993-2000: Director, Urologic Laparoscopic Surgery, Beth Israel Hospital
  • 1993: Fellowship, Beth Israel Hospital and Whitehead Institute of Biomedical Research
  • 1991: Urology Residency, Harvard Program in Urology
  • 1984: MD from Duke University School of Medicine


Colin P. N. Dinney, MD
Colin P. N. Dinney is the Chairman of the Department of Urology and a Professor in the Division of Surgery at The University of Texas M. D. Anderson Cancer Center.  He is the PI of the M. D. Anderson Genitourinary SPORE in Bladder Cancer Research, which was awarded in September of 2001. His bench and clinical research activities have focused on the biology of metastatic bladder cancer and on the development of novel therapeutic strategies for both early and advanced disease.

  • 2002-present: Professor, Departments of Urology and of Cancer Biology, Division of Surgery, The University of Texas MD Anderson Cancer Center
  • 1992: Fellow, Department of Urology, Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
  • 1989: Fellowship of Royal College of Physicians FRCP(S)
  • 1989: Research Fellowship, Urology, Dalhousie University, Halifax
  • 1986: Faculty of Medicine, Department of Surgery, Dalhousie University
  • 1984: Research Fellow, Department of Surgery, Dalhousie University
  • 1983: Rotating Internship, Medicine, Dalhousie University
  • 1982: University of Manitoba, Winnipeg, Canada, MD, Medicine
  • 1978: University of Manitoba, Winnipeg, Canada, BS, Microbiology

Seth Lerner, MD
Seth P. Lerner is a Professor of Urology in the Scott Department of Urology, Baylor College of Medicine. Co-editor of the widely used comprehensive Textbook of Bladder Cancer, Dr. Lerner is an active member of the American Association of Genitourinary surgeons.  He is co-chair of the National Cancer Institute’s Bladder Cancer Task Force and bladder cancer disease working group for The Cancer Genome Atlas Project. He chairs the Local Bladder Committee of SWOG and serves on the Board of Directors for the Bladder Cancer Advocacy Network. Dr. Lerner is the founder of the Bladder Cancer Research Consortium.

  • Professor, Department of Urology, Chair of Urologic Oncology
  • Fellowship, Urologic Oncology, USC School of Medicine
  • Residency, Urology, Baylor College of Medicine, Houston, TX
  • Residency, Surgery, Virginia Mason Hospital, Seattle, WA
  • AFUD/National Kidney Foundation fellowship and American Cancer Society fellowship in Urologic Oncology, University of Southern California
  • D., Baylor College of Medicine, Houston, TX